PMMA

Tachycardia documented at 110 mg (Shulgin). Sympathomimetic cardiovascular stress is compounded by PMMA's hyperthermic potential. Pre-existing cardiac conditions increase risk of arrhythmia and cardiovascular collapse.

PMMA's NET-mediated norepinephrine release produces blood pressure elevation. Pre-existing hypertension increases risk of hypertensive crisis or cardiovascular events.

Combination of PMMA's endogenous MAO-A inhibition with pharmaceutical MAOI therapy creates additive MAO blockade on top of PMMA's serotonin-releasing activity. Serotonin syndrome is near-certain.

PMMA's serotonin-releasing and MAO-A-inhibiting mechanisms combined with reuptake inhibition produces extreme serotonergic overload. No PMMA-specific case reports located but class-inferred risk is severe.

Reduced hepatic function may impair CYP2D6-mediated PMMA metabolism, leading to elevated blood concentrations and increased toxicity risk.

PMMA is a substrate of OCT2 for renal excretion (Jensen 2020). Impaired renal function may reduce drug elimination, contributing to accumulation.

CYP2D6 poor metabolizers (~5-10% of European populations) cannot adequately clear PMMA, resulting in drug accumulation. Given PMMA's narrow margin between active and lethal concentrations, impaired clearance may be fatal.

PMMA's sympathomimetic profile may interact dangerously with hyperthyroid states, both conditions independently producing tachycardia and elevated metabolic rate.

No specific PMMA teratogenicity data exist. Contraindicated on general pharmacological grounds as a sympathomimetic monoamine releaser with severe hyperthermic potential and documented lethality.